EBURY-PARTNERS
17.7.2019 08:32:11 CEST | Business Wire | Press release
Ebury, one of the UK and Europe’s largest fintechs, is pleased to announce it has entered into a partnership with Spain’s seventh largest bank, Unicaja Banco.
The agreement will enable Unicaja to offer international payments and cash management services through Ebury’s global transaction banking platform to its 400,000 SME customers and 3 million retail customers. Using Ebury’s regulated and future-proofed capabilities, Unicaja will significantly enhance its offering, particularly to its SME customer-base.
Unicaja´s customers can now make international payments in more than 100 currencies, collect over 40 currencies across Europe, APAC, Africa and South America, use dedicated currency accounts in over 20 countries, and access flexible foreign exchange risk management tools for over 130 currencies, via one platform 24/7, from any location.
The partnership demonstrates Ebury’s ability to help banks around the world by enabling them to offer their clients an innovative global transaction banking proposition. Not only do SMEs benefit from increased access to transaction banking products via a single platform, but the banks working with Ebury can deliver their global services quickly, at a very low cost.
Ebury currently serves over 35,000 small to mid-sized companies and institutions around the globe, executing over $2bn per month in transactions. Its rapid growth reflects the global trend of disintermediation of transaction services, as global banks focus on their core offerings.
Juan Lobato, Ebury’s Co-founder and CEO, commented: “I am delighted that Unicaja, one of Spain’s largest banks, has chosen to work with Ebury and will offer our customer-led services to its extensive client base. Our tailored solution is a cost-efficient way for Unicaja to reverse the trend of banks retrenching the services they provide to SMEs, and marks an important improvement in its capabilities.”
“This partnership is further validation of our strategy to deliver high-quality and efficient cross-border transactional services to small and medium companies that have difficulty accessing these services elsewhere on a single platform. In partnership with Ebury, banks can help businesses grow internationally while reducing the cost and risk of cross-border transactions”
Pablo Gonzalez, Unicaja Banco´s CFO, noted "Signing this agreement with Ebury, a leading Fintech specialising in cross-border payments, foreign exchange and cash management solutions to businesses, will give a huge competitive advantage to Unicaja Banco´s customers that currently trade internationally or wish to do so"
View source version on businesswire.com: https://www.businesswire.com/news/home/20190716005820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release
New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD) TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release
Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 12:00:00 CEST | Press release
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platformLilly to make a strategic investment in QurCan QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboratio
Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership15.9.2026 11:16:00 CEST | Press release
Live in six markets within twelve weeks of launch, with a 19,000-person waitlist Axo Longevity today announced the close of an oversubscribed $5M seed round to expand its preventive health membership across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910642125/en/ Axo Longevity preventive health membership The round was backed by MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital and NIAN Sports & Entertainment, alongside angel investors including Dr. Jorge Planas of Clinica Planas Barcelona and Daniel Kulle, former President of H&M and former CEO of Forever 21. Developed to help people understand what is happening inside their body before symptoms appear, Axo Longevity moved from build to live operations in just twelve weeks. The platform is expanding globally, now operating in the United Kingdom, Ireland, Spain, Germany, and the Netherlands, as well as in its
Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth15.9.2026 11:00:00 CEST | Press release
Highlights: David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026. Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins Chiesi from Flagship Pioneering. Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026. David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development. Following a thorough selection process led by the Board of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
